This hormone helps control how much insulin the body makes, how full you feel after eating, and how quickly food moves through your stomach
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, phase iiia, randomised trial
This is typically not clinically meaningful for weekly GLP-1 protocols, but if you track symptoms carefully and notice differences in timing of side effects or appetite suppression between sites, switching entirely to one site may provide more consistent results
Several clinical studies indicated that the rate of DNL is increased and responsible for around 2030% of fat accumulation in the liver in obese NAFLD patients [13, 16]
: ?